^
    Back
    Association details:
    Biomarker:ROS1 L2155S
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer

    Excerpt:
    In conclusion, we demonstrated that molecular changes associated with acquired resistance to crizotinib are heterogeneous in ROS1-rearranged NSCLC. ROS1 secondary mutations such as G2032R and L2155S, EGFR activation, and EMT were associated with acquired crizotinib resistance in ROS1-rearranged NSCLC.
    DOI:
    10.1158/1078-0432.CCR-14-1350
    Trial ID:
    PROFILE 1001